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COMMIT trials. METHODS: A combined decision tree and
Markov model was constructed. Since existing evidence indicates
similar long-term outcomes after STEMI and NSTEMI, data
from the long-term NSTEMI CURE trial was combined with 1-
month data from CLARITY and COMMIT to model the effect
of treatment up to one year. The risk of death, MI and stroke in
an untreated population and long-term survival were derived
from the Swedish hospital and death registers. The model was
run separately for the two STEMI trials. A payer perspective was
chosen for the main analysis, focusing on direct medical costs.
Costs for Sweden, Germany and France were based on published
sources and were converted to 2005 Euros. Effectiveness was
measured as the number of life-years gained (LYG) from clopi-
dogrel treatment. RESULTS: Using a patient cohort with the
same characteristics and event rates as the CLARITY popula-
tion, adding clopidogrel to aspirin treatment for up to one year
resulted in 0.14 LYG. In Sweden and France, this strategy was
dominant with estimated cost savings of €110 and €370, respec-
tively. In Germany, clopidogrel treatment had an incremental
cost-effectiveness ratio (ICER) of €120/LYG. Using data from the
COMMIT study, clopidogrel treatment resulted in 0.19 LYG at
an incremental cost of €530 in Sweden, €540 in France and €790
in Germany. The corresponding ICERs were €2760/LYG,
€2760/LYG and €4130/LYG, respectively. CONCLUSIONS:
Treatment of STEMI patients with clopidogrel for up to one year
is cost-effective in all three European countries studied, with pre-
dicted ICERs well below generally accepted thresholds.
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OBJECTIVE: Pacemaker implantation is an established
approach to bradycardia due to sinoatrial node disease or 
atrioventricular block. A new kind of pacing system (managed
ventricular pacing), has been developed recently to avoid 
unnecessary pacing in the right ventricle. The objective is to eval-
uate the long term clinical and economic consequences, associ-
ated with the use of Adapta pacemakers, (which allow for
managed ventricular pacing) versus the standard dual chamber
pacemakers (DDDR) in a Spanish Hospital (Valencia General
Hospital), where pacemakers are implanted through ambulatory
surgery. Costs and beneﬁts were discounted at 3%. METHODS:
A lifetime discrete event simulation model was adapted to the
Spanish setting, simulating clinical evolution of bradycardia,
after a pacemaker implantation. Pairs of identical patients are
created, and one receives Adapta while the other a DDDR. Clin-
ical and utility data were obtained from published trials (MOST,
PASE) Distributions of ventricular pacing are based on data col-
lected during trials of these devices. Cost data came from Valen-
cia General Hospital costs database. Age and gender population
data were obtained from the Spanish Registry of Pacemakers
from the Spanish Society of Cardiology. RESULTS: Based on 100
replications of a hypothetical cohort, treating patients with
Adapta versus dual chamber pacemakers results in mean a saving
of €397 per patient. Adapta implantation is predicted to result
in a 65.4% decrease in heart failure hospitalization, a 16.5%
decrease in atrial ﬁbrillation, and an 11% reduction in the
number of strokes experienced. The model predicts an increase
of 0.29 QALYs per patient treated with managed ventricular
pacing; the Adapta device is dominant compared to DDDR.
CONCLUSIONS: Based on these estimates use of MVP vs. dual
chamber devices, in patients with bradycardia is an efﬁcient
strategy in the Spanish setting, providing better long-term clini-
cal and economic outcomes.
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OBJECTIVES: Although the importance of hypertension as a
risk factor for cardiovascular disease (CVD) is well know, blood
pressure remains uncontrolled in a signiﬁcant part of patients.
The aim of this study was to assess the cost-effectiveness of
adding olmesartan, a angiotensin-II-antagonist, to treatment in
patients with uncontrolled hypertension. Belgium was used as a
case country. METHODS: A Markov model with a 10-year time
horizon using 6-month cycles was developed in MSExcel.
Depending on age, smoking status, systolic blood pressure (SBP),
and total cholesterol, fatal CVD risk (cardiac death, fatal stroke)
was calculated using the SCORE equation for patients without
a history of CVD and using the Framingham equation for
patients with a history of CVD (18%). Non-fatal risk was indi-
rectly calculated based on landmark primary prevention trials.
Clinical data were obtained from the Belgian 12-week Olme-R3-
study (Olmetec Real-life Responder Rate-study) in which 4130
patients with uncontrolled hypertension were started on olmes-
tartan (10, 20 or 40 mg at the physician’s discretion-74%
received 20 mg) assuming that effects are maintained over 10-
years. Direct costs from the Belgian payers’ perspective were
included. Ofﬁcial sources for cost of events and cost of drugs
were used. The unit costs of olmesartan, 10, 20 and 40 mg are
respectively €0.70, €0.50 and €0.63 (10 mg more expensive due
to pack-size). Annual discounting of 3% was applied on cost and
effects. RESULTS: At 12 weeks, adding olmesartan decreased
SBP with 22.47 mmHg (95%CI 22.00–22.94 mmHg—baseline
SBP 160 mmHg) and decreased the number of antihypertensive
drugs needed. The cost of antihypertensive treatment increased
from €0.54 to €0.73 (part olmesartan €0.53) per day. Applying
the observed SBP effect to the 10-year model results in a 
incremental cost-effectiveness ratio of €9813/LYG (95%CI
€9568/LYG-€10,073/LYG). CONCLUSIONS: Adding olmesar-
tan to antihypertensive treatment in patients with uncontrolled
hypertension seems cost-effective from the perspective of the
health care payer.
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OBJECTIVES: Patients presenting a cluster of cardiometabolic
risk factors (CMRF) are at increased risk of developing cardio-
vascular disease (CVD). One possible clustering is the metabolic
syndrome (MS). We investigated the long-term outcomes associ-
ated with MS in a Swiss population. METHODS: A computer
simulation model was developed to project life expectancy (LE)
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and costs of treating CVD complications in Swiss patients with
and without MS, using the National Cholesterol Education
Program Adults Treatment panel III (NCEP/ATP III) deﬁnition.
The 5-state Markov model utilized predictive regression equa-
tions and transition probabilities from the Framingham and
PROCAM epidemiological studies. Patient characteristics were
taken from the Lausanne Health Promotion Database which
consisted of 9401 patients aged 18 to 79 years. Patients in the
database were segmented according to their status of meeting the
criteria of having MS, CMRF, and their age. Direct medical costs
were accounted in 2005 Swiss Francs (CHF). Outcomes were
projected over a lifetime horizon and discounted at 5% per
annum. RESULTS: The presence of MS was projected to result
in decreased LE by 2.29 years (16.27 vs 13.98 years) compared
to individuals without the syndrome. The presence of MS was
consistently associated with lower LE in all patient age groups.
Direct medical costs of treating CVD complications in patients
with MS were CHF 4413 higher than patients without the 
syndrome (CHF 8382 vs. CHF 3969). The largest differences in
cost were estimated for patients aged above 75 years (CHF
11,744 vs. CHF 6707). CONCLUSIONS: On the basis of the
NCEP/ATP III deﬁnition, our modeling analysis concludes that
the presence of MS decreases LE (−2.29 years) and increases
CVD costs (CHF 4413) per patient in the Swiss setting. These
data suggest that the costs of future interventions targeted at 
the causes/management of MS could be offset by reduced CVD
costs.
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OBJECTIVES: Atrial ﬁbrillation (AF) is the most common
arrhythmic condition, with rising prevalence. AF increases stroke
and mortality rates. Ablation (percutaneous and surgical) pro-
vides a more permanent solution to AF compared to drugs and
reduces stroke and mortality rates. Performing surgical ablation
(SA) concomitantly to cardiac surgery (CABG or valvular repair)
only lengthens surgery with maximum 30 min without increas-
ing complication rates. The aim of this study was to assess the
cost-effectiveness of concomitant SA for permanent AF, with the
UK as a case country. METHODS: A Markov model, compar-
ing no ablation during surgery (NSA) with concomitant SA for
AF, was developed in TreeAge. The initial cardiac surgery (with
or without SA) can result in short-term complications (mortal-
ity, stroke, bleeding leading to re-surgery, and pacemaker
implantation) or not. 4 different health states were deﬁned: sinus
rhythm without complications, AF without complications,
history of stroke and death. Every 3 months (for a total of 5
years) the patient had a risk to die or to have a stroke or an AF
recurrence. Clinical data were derived from published data (3-
month free of AF after SA 81% vs. 23% for NSA). Direct costs
from the NHS (2006) perspective were used. The cost of SA was
assumed to be GBP2500. Utility data (TTO) were obtained from
published data and from the Euro Heart Survey (utility perma-
nent AF = 0.78). Costs and effects were discounted at 3.5%
annually. RESULTS: Over the 5-year modeling period SA
resulted in 0.427 QALY gained (3.079 QALY vs. 2.652 QALY)
for an additional cost of GBP2054 (GBP4567 vs. GBP2513). The
incremental cost-effectiveness ratio (ICER) was GBP4810/
QALYG. Doubling the modelling period decreased ICER with
50%. Increasing utility of AF to 0.97 increased ICER to
GBP19,106/QALYG. CONCLUSIONS: Compared to no abla-
tion, concomitant SA is a cost-effective treatment for AF in the
UK.
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Hypertension is a common condition leading to increased risk of
excess mortality and morbidity from cardiovascular events (AMI
and stroke). Furthermore, it is known that blood pressure reduc-
tion of 2–5 mmHg has an impact on the patients risk for car-
diovascular events and mortality. In a double blinded RCT
irbesartan 300 mg reduced systolic blood pressure by 16.4
mmHg while losartan 100 mg reduced blood pressure by 11.3
mmHg. P value was signiﬁcant (p < 0.05). OBJECTIVE: To
assess the cost-effectiveness of long-term treatment of hyperten-
sion with irbesartan vs. losartan in a Danish setting.
METHODS: A Markov model was developed using the SCORE
risk function to predict cardiovascular events depending on
blood pressure level and other risk factors. The effect of irbe-
sartan and losartan was taken from a RCT study with direct
comparison (the Kassler-Taub study). In this study, irbesartan
was also compared to no treatment. In the model, lifelong treat-
ment was evaluated with either early intervention, when hyper-
tension occurs (age 55), or late intervention after the occurrence
of the ﬁrst cardiovascular event. Health outcomes were number
of cardiovascular events, life years and QALYs gained. Danish
costs and epidemiological data were applied. RESULTS: Irbe-
sartan was shown to be cost-saving vs. losartan (−€5.950/LYG).
Compared to placebo, early intervention was shown to be more
cost-effective relative to late intervention. CONCLUSIONS:
Long-term treatment of hypertension with irbesartan can be
cost-saving compared to treatment with losartan.
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OBJECTIVES: Bivalirudin, a selective thrombin inhibitor, has
been approved as an alternative treatment to the use of heparin
in patients undergoing percutaneous coronary intervention
(PCI). The objective is to evaluate the efﬁciency measured as the
health care costs savings, due to the replacement of the current
heparin plus glycoprotein IIb/IIIa inhibition (abciximab) by
bivalirudin in patients undergoing PCI. METHODS: Regarding
the incidence of ischaemic events, it has been proved the equiv-
alence between heparin plus inhibitors of glycoprotein and
bivalirudin, noticing a smaller rate of bleeding complications in
the group treated with bivalirudin (REPLACE 2). Based on this
ﬁnding a cost minimization analysis (CMA) has been carried out
focusing on the differential costs when using both treatments:
the drug cost, the cost of major bleeding management (bleeding
at puncture point and digestive bleeding). Two experts in inter-
